• LAST PRICE
    0.0240
  • TODAY'S CHANGE (%)
    Trending Up0.0039 (19.4030%)
  • Bid / Lots
    0.0219/ 481
  • Ask / Lots
    0.0240/ 754
  • Open / Previous Close
    0.0204 / 0.0201
  • Day Range
    Low 0.0201
    High 0.0240
  • 52 Week Range
    Low 0.0190
    High 0.0679
  • Volume
    747,050
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.0201
TimeVolumeIPIX
09:39 ET11400.0202
09:53 ET289000.0202
10:00 ET106000.0202
10:11 ET1000000.024
10:13 ET10000.0203
10:18 ET1540000.0201
10:20 ET1650000.024
10:24 ET250000.022
10:27 ET280000.022
10:31 ET1200000.0204
10:33 ET1000000.024
10:38 ET2000.0218
10:40 ET100000.02215
11:32 ET20000.024
11:50 ET4100.023
01:56 ET8000.024
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIPIX
Innovation Pharmaceuticals Inc
10.1M
-1.9x
---
United StatesONCR
Oncorus Inc
10.2M
-0.1x
---
United StatesBPTS
Biophytis SA
9.6M
-0.1x
---
United StatesNEXI
Neximmune Inc
10.2M
-0.1x
---
United StatesGBLX
GB Sciences Inc
9.7M
-49.0x
---
United StatesVRPX
Virpax Pharmaceuticals Inc
9.6M
-0.4x
---
As of 2022-12-08

Company Information

Innovation Pharmaceuticals Inc. is a clinical-stage pharmaceutical company, which is engaged in developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company is in the business of developing small molecule therapies to treat diseases with medical need, particularly in the areas of inflammatory diseases, cancer, dermatology and anti-infectives. The Company is primarily focused on the advancement of Brilacidin in Oral Mucositis and in infectious diseases. Brilacidin is Company’s lead drug candidate in Host Defense Protein (HDP)-mimetic franchise. Brilacidin is a de novo-designed synthetic, non-peptidic, small molecule that kills pathogens swiftly, greatly reducing the likelihood of drug resistance developing. It also functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities.

Contact Information

Headquarters
301 EDGEWATER PLACE, SUITE 100WAKEFIELD, MA, United States 01880
Phone
978-921-4125
Fax
978-921-6564

Executives

Chairman of the Board, Chief Executive Officer, Chief Financial Officer
Leo Ehrlich
Senior Vice President - Clinical Sciences and Portfolio Management
Jane Harness
Independent Director
Barry Schechter
Independent Director
Zorik Spektor

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.1M
Revenue (TTM)
$18.0K
Shares Outstanding
504.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.13
EPS
$-0.01
Book Value
$0.01
P/E Ratio
-1.9x
Price/Sales (TTM)
562.8
Price/Cash Flow (TTM)
---
Operating Margin
-34,105.55%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.